VRCAVerrica Pharmaceuticals Inc.

Nasdaq verrica.com


$ 6.86 $ 0.22 (3.31 %)    

Friday, 26-Apr-2024 15:59:27 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 6.87
$ 6.85
$ 0.00 x 0
$ 0.00 x 0
$ 6.85 - $ 6.89
$ 2.86 - $ 7.76
111,046
na
311.5M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-06-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-02-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-17-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-13-2020 12-31-2019 10-K
18 11-06-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-8-price-target

Needham reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

 verrica-pharmaceuticals-lead-product-ycanth-has-received-new-chemical-entity-status-and-a-listing-in-the-orange-book-from-the-fda-providing-a-minimum-of-five-years-of-regulatory-exclusivity

NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent appl...

 needham-reiterates-buy-on-verrica-pharmaceuticals-maintains-8-price-target

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

 hc-wainwright--co-maintains-buy-on-verrica-pharmaceuticals-raises-price-target-to-13

HC Wainwright & Co. analyst Oren Livnat maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price ...

 verrica-pharmaceuticals-q4-eps-053-inline-sales-199m-beat-91000k-estimate

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate. ...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 top-4-health-care-stocks-that-may-crash-this-month

As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

 insiders-buying-pfizer-and-3-other-stocks

Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.

 jefferies-reiterates-buy-on-verrica-pharmaceuticals-maintains-10-price-target

Jefferies analyst Glen Santangelo reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $10 price target.

 why-quanex-building-products-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth...

 why-is-skin-disease-focused-verrica-pharmaceuticals-stock-trading-higher-today

Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, report...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION